Evidence map›Paper›PMID 35475677›Full record

ArticleCancer control : journal of the Moffitt Cancer Center

Clinicogenomic Characteristics and Treatment of Young-Onset Colorectal Cancer Patients Treated With Palliative Therapy in Real-World Practice.

Hyehyun Jeong, Eunjung Lee, Deokhoon Kim, Jihun Kim, Sun Young Kim, Yong Sang Hong, Tae Won Kim, Jeong Eun Kim

Open access · goldAbstract read
In one paragraph

Article in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.1field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Hyehyun JeongDepartment of Oncology, 65526University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.ORCID https://orcid.org/0000-0001-7277-6463
Eunjung LeeDepartment of Medical Science, 65526University of Ulsan College of Medicine, Asan Medical Institute of Convergence Science and Technology, Asan Medical Center, Seoul, Republic of Korea.ORCID https://orcid.org/0000-0001-8598-0498
Deokhoon KimDepartment of Medical Science, 65526University of Ulsan College of Medicine, Asan Medical Institute of Convergence Science and Technology, Asan Medical Center, Seoul, Republic of Korea.
Jihun KimDepartment of Pathology, 65526University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.ORCID https://orcid.org/0000-0002-8694-4365
Sun Young KimDepartment of Oncology, 65526University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
Yong Sang HongDepartment of Oncology, 65526University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
Tae Won KimDepartment of Oncology, 65526University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
Jeong Eun KimDepartment of Oncology, 65526University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
Ulsan College · KR

Funding

Rochester Center for Adolescent Immunization ResearchU01IP000040 · IP · UNIVERSITY OF ROCHESTER · PI SZILAGYI, PETER G · 2004 to 2006
$273k
NCIRD CDC HHS U01 IP000040
6 · The paper itself

Abstract

introductionYoung-onset colorectal cancer (YOCR) is increasing. This study aimed to determine the difference between advanced YOCR and non-YOCR patient outcomes.

methodsWe retrospectively included patients with recurrent/metastatic colorectal cancer treated with palliative systemic therapy between 2016 and 2018. Diagnosis at < 50 years was defined as YOCR. Targeted sequencing was used to assess the mutational status.

resultsAmong the 969 patients included, 210 (21.7%) were YOCR. The median progression-free survival with first-line chemotherapy (PFS1) was 9.7 vs 9.4 months (

conclusionsSurvival outcomes with palliative systemic therapy were similar between recurrent/metastatic YOCR and non-YOCR with an age cut-off of 50 years. However, patients diagnosed at < 30 years of age showed poorer outcomes compared with other age groups.

Indexed as

Colonic NeoplasmsColorectal NeoplasmsRectal NeoplasmsBiomarkers, TumorHumansMicrosatellite InstabilityMiddle AgedPalliative CareProto-Oncogene Proteins B-rafRetrospective StudiesBiomarkers, TumorProto-Oncogene Proteins B-rafcolorectal cancerpalliative chemotherapytargeted sequencingtumor mutational burdenyoung-onset colorectal cancer

Identifiers

PMID35475677
PMCPMC9087235
OpenAlexW4225005368

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.